A Simplified Method to Determine Five Cytochrome P450 Probe Drugs by HPLC in a Single Run

被引:29
作者
Liu, Ying [1 ,2 ]
Jiao, Hanjie [1 ]
Zhang, Caili [1 ]
Lou, Jianshi [1 ]
机构
[1] Tianjin Med Univ, Dept Pharmacol, Coll Basic Med, Tianjin 300070, Peoples R China
[2] Tianjin Ctr ADR Monitoring, Tianjin 300070, Peoples R China
关键词
cytochrome P450; probe drug; cocktail approach; HPLC; COCKTAIL APPROACH; METABOLITES; ENZYMES; PLASMA; URINE;
D O I
10.1248/bpb.32.717
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A simplified, rapid, selective HPLC method for determining five cytochrome P450 (CYP) probe drugs in single run is described. The five specific probe substrates of caffeine, chlorzoxazone, tolbutamide, metoprolol and midazolam, together with the internal standard diazepam, were extracted using liquid-liquid extraction in rat plasma, followed by high-performance liquid chromatography (HPLC) using a C,, column (5 mu m particle size, 250 x 4.6 mm W.). The mobile phase consisted of a methanol and 50 mm phosphate buffer (pH 3.4, 65: 35). All analytes were separated simultaneously in a single run that lasted less than 22 min. The detection limits range from 0.2-50 mu g/ml for caffeine, 0.5-50 mu g/ml for tolbutamide, metoprolol and midazolam, 0.2-100 mu g/ml for chlorzoxazone, respectively. The intra- and inter-day precisions for five probe substrates were 1.38-11.10% and 3.39-11.33%, respectively, and the accuracy of five probe substrates ranged from 94.92-113.06% and 92.18-112.62%. The limit of quantification (LOQ) was 0.5 mu g/ml for tolbutamide, midazolam and metoprolol, 0.2 mu g/ml for caffeine and chlorzoxazone. The present method provides a robust, fast analytical tool for the five-probe drug cocktail. Finally, the method was suitable for determining the plasma concentration of these compounds and evaluating the CYP1A2, 2C9, 2D6, 2E1 and 3A4 activities in rats.
引用
收藏
页码:717 / 720
页数:4
相关论文
共 14 条
[1]   Pharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1 [J].
Blakey, GE ;
Lockton, JA ;
Perrett, J ;
Norwood, P ;
Russell, M ;
Aherne, Z ;
Plume, J .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 57 (02) :162-169
[2]   A COCKTAIL STRATEGY TO ASSESS INVIVO OXIDATIVE DRUG-METABOLISM IN HUMANS [J].
BREIMER, DD ;
SCHELLENS, JHM .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1990, 11 (06) :223-225
[4]   The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes [J].
Christensen, M ;
Andersson, K ;
Dalén, P ;
Mirghani, RA ;
Muirhead, GJ ;
Nordmark, A ;
Tybring, G ;
Wahlberg, A ;
Yasar, Ü ;
Bertilsson, L .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (06) :517-528
[5]   Validation of the five-drug ''Pittsburgh cocktail'' approach for assessment of selective regulation of drug-metabolizing enzymes [J].
Frye, RF ;
Matzke, GR ;
Adedoyin, A ;
Porter, JA ;
Branch, RA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 62 (04) :365-376
[6]   A simplified analytical method for a phenotyping cocktail of major CYP450 biotransformation routes [J].
Jerdi, MC ;
Daali, Y ;
Oestreicher, MK ;
Cherkaoui, S ;
Dayer, P .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2004, 35 (05) :1203-1212
[7]   Drug-drug interactions in the metabolism of imidafenacin: Role of the human cytochrome P450 enzymes and UDP-glucuronic acid transferases, and potential of imidafenacin to inhibit human cytochrome P450 enzymes [J].
Kanayama, N. ;
Kanari, C. ;
Masuda, Y. ;
Ohmori, S. ;
Ooie, T. .
XENOBIOTICA, 2007, 37 (02) :139-154
[8]   Investigation of sarizotan's impact on the pharmacokinetics of probe drugs for major cytochrome P450 isoenzymes:: a combined cocktail trial [J].
Krösser, S ;
Neugebauer, R ;
Dolgos, H ;
Fluck, M ;
Rost, KL ;
Kovar, A .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (04) :277-284
[9]  
Scott RJ, 1999, RAPID COMMUN MASS SP, V13, P2305, DOI 10.1002/(SICI)1097-0231(19991215)13:23<2305::AID-RCM790>3.0.CO
[10]  
2-G